Katherine Karakasis

610 University Avenue
Toronto, ON M5G2M9, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery.

Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery.

Journal: Cancers

Published: May 13, 2023

Management of Malignant Bowel Obstruction: An Innovative Proactive Outpatient Nurse-Led Model of Care for Patients With Advanced Gynecologic Cancer.

Management of Malignant Bowel Obstruction: An Innovative Proactive Outpatient Nurse-Led Model of Care for Patients With Advanced Gynecologic Cancer.

Journal: Journal of nursing care quality

Published: October 10, 2022

Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma.

Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma.

Journal: Gynecologic oncology

Published: May 12, 2022

Updates on systemic therapy for cervical cancer.

Updates on systemic therapy for cervical cancer.

Journal: The Indian journal of medical research

Published: March 17, 2022

Advances in ovarian cancer, from biology to treatment.

Advances in ovarian cancer, from biology to treatment.

Journal: Nature cancer

Published: February 05, 2022

Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers.

Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers.

Journal: Cancers

Published: January 07, 2022

With Our Powers Combined: Exploring PARP Inhibitors and Immunotherapy.

With Our Powers Combined: Exploring PARP Inhibitors and Immunotherapy.

Journal: Cancer journal (Sudbury, Mass.)

Published: December 14, 2021

Ethical frameworks in clinical research processes during COVID-19: a scoping review.

Ethical frameworks in clinical research processes during COVID-19: a scoping review.

Journal: BMJ open

Published: July 24, 2021

Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series.

Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series.

Journal: Gynecologic oncology reports

Published: November 06, 2020

Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature.

Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature.

Journal: Current oncology (Toronto, Ont.)

Published: November 02, 2020

Measuring Quality of Life in Ovarian Cancer Clinical Trials-Can We Improve Objectivity and Cross Trial Comparisons?

Measuring Quality of Life in Ovarian Cancer Clinical Trials-Can We Improve Objectivity and Cross Trial Comparisons?

Journal: Cancers

Published: September 30, 2020

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.

Journal: Lancet (London, England)

Published: September 14, 2020

Showing 1-12 of 38

Last Updated: 09/26/2026